Close Sidebar
Nordic Life Science
Now Reading
Evaxion announces increased focus and fast-tracking of its new AI discovery to patients
Search for content, post, videos
Search for content, post, videos

Evaxion announces increased focus and fast-tracking of its new AI discovery to patients

March 29, 2023
937 Views
The company has announced an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline. Recently, Evaxion announced that the company has used its AI technology to discover a new treatment opportunity that may broaden cancer immunothera
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

December 21, 2022

Swedish Anocca has secured Venture Debt financing from the European Investment Bank (EIB). This significant investment recognizes the strength and high potential of Anocca and its transformational approach to developing T-cell therapies for cancer, the company states. "This financing supports usAlready a subscriber Login You have read all your free…

January 19, 2022

The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights Issue is to finance the continued development of the company and its projects in accordance with its business plan Already…

sean_bohen_AZ
December 14, 2016

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb), and granted priority review status with a PrescriAlready a subscriber Login You have read all…

Jakob Lindberg
December 8, 2022

Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto. The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significaAlready a subscriber…